Esperion Therapeutics | ESPR - Ativos





Ativos Alterar Data
AbbVie USD 133.96B 62M 2025-12
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
Amarin USD 645.76M 25.01M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Cipla INR 401.64B 27.77B 2025-09
CSL USD 37.9B 1.5B 2025-12
Cytokinetics USD 1.27B 151.06M 2026-03
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Geron USD 570.54M 3.16M 2025-12
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 11.49B 850M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12